Activity and Toxicity of Pembrolizumab for NSCLC
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).
Activity
- Pembrolizumab has been explored in NSCLC in the first-line and in previously treated patients.
- Good activity has been seen in PD-L1-positive patients.
Toxicity
- Pembrolizumab is generally well tolerated and elicited few significant adverse events.
- Some mild fatigue and pruritus were reported.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
